134 related articles for article (PubMed ID: 35722822)
1. The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.
Natsume A; Arakawa Y; Narita Y; Sugiyama K; Hata N; Muragaki Y; Shinojima N; Kumabe T; Saito R; Motomura K; Mineharu Y; Miyakita Y; Yamasaki F; Matsushita Y; Ichimura K; Ito K; Tachibana M; Kakurai Y; Okamoto N; Asahi T; Nishijima S; Yamaguchi T; Tsubouchi H; Nakamura H; Nishikawa R
Neuro Oncol; 2023 Feb; 25(2):326-336. PubMed ID: 35722822
[TBL] [Abstract][Full Text] [Related]
2. Mutant IDH1 and thrombosis in gliomas.
Unruh D; Schwarze SR; Khoury L; Thomas C; Wu M; Chen L; Chen R; Liu Y; Schwartz MA; Amidei C; Kumthekar P; Benjamin CG; Song K; Dawson C; Rispoli JM; Fatterpekar G; Golfinos JG; Kondziolka D; Karajannis M; Pacione D; Zagzag D; McIntyre T; Snuderl M; Horbinski C
Acta Neuropathol; 2016 Dec; 132(6):917-930. PubMed ID: 27664011
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent
Fanucci K; Pilat MJ; Shyr D; Shyr Y; Boerner S; Li J; Durecki D; Drappatz J; Puduvalli V; Lieberman FS; Gonzalez J; Giglio P; Ivy SP; Bindra RS; Omuro A; LoRusso P
Cancer Res Commun; 2023 Feb; 3(2):192-201. PubMed ID: 36968138
[TBL] [Abstract][Full Text] [Related]
4. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff IK; van den Bent MJ; Blumenthal DT; Touat M; Peters KB; Clarke J; Mendez J; Yust-Katz S; Welsh L; Mason WP; Ducray F; Umemura Y; Nabors B; Holdhoff M; Hottinger AF; Arakawa Y; Sepulveda JM; Wick W; Soffietti R; Perry JR; Giglio P; de la Fuente M; Maher EA; Schoenfeld S; Zhao D; Pandya SS; Steelman L; Hassan I; Wen PY; Cloughesy TF;
N Engl J Med; 2023 Aug; 389(7):589-601. PubMed ID: 37272516
[TBL] [Abstract][Full Text] [Related]
5. Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat.
Chang CM; Ramesh KK; Huang V; Gurbani S; Kleinberg LR; Weinberg BD; Shim H; Shu HG
Tomography; 2023 May; 9(3):942-954. PubMed ID: 37218937
[TBL] [Abstract][Full Text] [Related]
6. Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.
Tap WD; Villalobos VM; Cote GM; Burris H; Janku F; Mir O; Beeram M; Wagner AJ; Jiang L; Wu B; Choe S; Yen K; Gliser C; Fan B; Agresta S; Pandya SS; Trent JC
J Clin Oncol; 2020 May; 38(15):1693-1701. PubMed ID: 32208957
[TBL] [Abstract][Full Text] [Related]
7. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
Mellinghoff IK; Lu M; Wen PY; Taylor JW; Maher EA; Arrillaga-Romany I; Peters KB; Ellingson BM; Rosenblum MK; Chun S; Le K; Tassinari A; Choe S; Toubouti Y; Schoenfeld S; Pandya SS; Hassan I; Steelman L; Clarke JL; Cloughesy TF
Nat Med; 2023 Mar; 29(3):615-622. PubMed ID: 36823302
[TBL] [Abstract][Full Text] [Related]
8. De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma.
Shi DD; Savani MR; Levitt MM; Wang AC; Endress JE; Bird CE; Buehler J; Stopka SA; Regan MS; Lin YF; Puliyappadamba VT; Gao W; Khanal J; Evans L; Lee JH; Guo L; Xiao Y; Xu M; Huang B; Jennings RB; Bonal DM; Martin-Sandoval MS; Dang T; Gattie LC; Cameron AB; Lee S; Asara JM; Kornblum HI; Mak TW; Looper RE; Nguyen QD; Signoretti S; Gradl S; Sutter A; Jeffers M; Janzer A; Lehrman MA; Zacharias LG; Mathews TP; Losman JA; Richardson TE; Cahill DP; DeBerardinis RJ; Ligon KL; Xu L; Ly P; Agar NYR; Abdullah KG; Harris IS; Kaelin WG; McBrayer SK
Cancer Cell; 2022 Sep; 40(9):939-956.e16. PubMed ID: 35985343
[TBL] [Abstract][Full Text] [Related]
9. PRMT1 driven PTX3 regulates ferritinophagy in glioma.
Lathoria K; Gowda P; Umdor SB; Patrick S; Suri V; Sen E
Autophagy; 2023 Jul; 19(7):1997-2014. PubMed ID: 36647288
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of histopathological features of paired recurrent gliomas: a cohort study from a single cancer center.
Li C; Xi S; Chen Y; Guo C; Zhang J; Yang Q; Wang J; Sai K; Zeng J; Wang J; Zhang Z; Ke C; Chen Z
BMC Cancer; 2023 Jan; 23(1):8. PubMed ID: 36597096
[TBL] [Abstract][Full Text] [Related]
11. Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase-mutant Astrocytic and Oligodendroglial Tumors.
Kamson DO; Puri S; Sang Y; Shi MJ; Blair L; Blakeley JO; Laterra J
Clin Cancer Res; 2023 Dec; 29(23):4863-4869. PubMed ID: 37382607
[TBL] [Abstract][Full Text] [Related]
12. HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma.
Garrett MC; Albano R; Carnwath T; Elahi L; Behrmann CA; Pemberton M; Woo D; O'Brien E; VanCauwenbergh B; Perentesis J; Shah S; Hagan M; Kendler A; Zhao C; Paranjpe A; Roskin K; Kornblum H; Plas DR; Lu QR
Sci Rep; 2023 Aug; 13(1):12433. PubMed ID: 37528157
[TBL] [Abstract][Full Text] [Related]
13. State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.
Schaff LR; Ioannou M; Geurts M; van den Bent MJ; Mellinghoff IK; Schreck KC
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e431450. PubMed ID: 38723228
[TBL] [Abstract][Full Text] [Related]
14. Targeted Options for Glioma Looking Good.
Cancer Discov; 2023 Aug; 13(8):1755. PubMed ID: 37276325
[TBL] [Abstract][Full Text] [Related]
15. Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip.
Cui H; Sun X; Schilling M; Herold-Mende C; Reischl M; Levkin PA; Popova AA; Turcan Ş
Adv Healthc Mater; 2023 Sep; 12(24):e2300591. PubMed ID: 37162029
[TBL] [Abstract][Full Text] [Related]
16. EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor.
Sprinzen L; Garcia F; Mela A; Lei L; Upadhyayula P; Mahajan A; Humala N; Manier L; Caprioli R; Quiñones-Hinojosa A; Casaccia P; Canoll P
Cells; 2024 Jan; 13(3):. PubMed ID: 38334611
[TBL] [Abstract][Full Text] [Related]
17. Integrated genomic characterization of IDH1-mutant glioma malignant progression.
Bai H; Harmancı AS; Erson-Omay EZ; Li J; Coşkun S; Simon M; Krischek B; Özduman K; Omay SB; Sorensen EA; Turcan Ş; Bakırcığlu M; Carrión-Grant G; Murray PB; Clark VE; Ercan-Sencicek AG; Knight J; Sencar L; Altınok S; Kaulen LD; Gülez B; Timmer M; Schramm J; Mishra-Gorur K; Henegariu O; Moliterno J; Louvi A; Chan TA; Tannheimer SL; Pamir MN; Vortmeyer AO; Bilguvar K; Yasuno K; Günel M
Nat Genet; 2016 Jan; 48(1):59-66. PubMed ID: 26618343
[TBL] [Abstract][Full Text] [Related]
18. IDH-mutant glioma: A new IDH1 inhibitor moves forward.
Miller JJ; Arrillaga-Romany I
Neuro Oncol; 2023 Feb; 25(2):337-338. PubMed ID: 36526609
[No Abstract] [Full Text] [Related]
19. A Promising Breakthrough: The Potential of VORASIDENIB in the Treatment of Low-grade Glioma.
Bombino A; Magnani M; Conti A
Curr Mol Pharmacol; 2024 Feb; ():. PubMed ID: 38425121
[TBL] [Abstract][Full Text] [Related]
20. Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.
Wang QX; Zhang PY; Li QQ; Tong ZJ; Wu JZ; Yu SP; Yu YC; Ding N; Leng XJ; Chang L; Xu JG; Sun SL; Yang Y; Li NG; Shi ZH
Eur J Med Chem; 2023 Sep; 257():115464. PubMed ID: 37235998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
